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Abstract
Background: There is growing awareness of secondary insulin resistance and alterations in myocardial glucose utilization in
congestive heart failure. Whether therapies that directly target these changes would be beneficial is unclear. We previously
demonstrated that acute blockade of the insulin responsive facilitative glucose transporter GLUT4 precipitates acute
decompensated heart failure in mice with advanced dilated cardiomyopathy. Our current objective was to determine
whether pharmacologic enhancement of insulin sensitivity and myocardial glucose uptake preserves cardiac function and
survival in the setting of primary heart failure.
Methodology/Principal Findings: The GLP-1 agonist exenatide was administered twice daily to a murine model of dilated
cardiomyopathy (TG9) starting at 56 days of life. TG9 mice develop congestive heart failure and secondary insulin resistance
in a highly predictable manner with death by 12 weeks of age. Glucose homeostasis was assessed by measuring glucose
tolerance at 8 and 10 weeks and tissue 2-deoxyglucose uptake at 75 days. Exenatide treatment improved glucose tolerance,
myocardial GLUT4 expression and 2-deoxyglucose uptake, cardiac contractility, and survival over control vehicle-treated
TG9 mice. Phosphorylation of AMP kinase and AKT was also increased in exenatide-treated animals. Total myocardial GLUT1
levels were not different between groups. Exenatide also abrogated the detrimental effect of the GLUT4 antagonist ritonavir
on survival in TG9 mice.
Conclusion/Significance: In heart failure secondary insulin resistance is maladaptive and myocardial glucose uptake is
suboptimal. An incretin-based therapy, which addresses these changes, appears beneficial.
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Introduction
Despite significant advances, congestive heart failure remains a
major cause of morbidity and mortality. Standard medical therapy
for congestive heart failure includes the use of ACE inhibitors,
angiotensin receptor antagonists, and b-blockers, which inhibit
maladaptive neurohormonal signaling pathways. Insulin resistance
is also recognized as a common metabolic response to heart failure
[1,2]. Modulation of the delivery to and expenditure of energy in
the heart under situations of acute and chronic stress hence has
garnered growing interest [3]. Solid evidence indicates that the
failing heart is chronically energy depleted, but the specific
contributions of reduced energy supply and increased energy
utilization remain incompletely characterized. Thus, drugs that
enhance insulin sensitivity, myocardial glucose uptake or both
have been proposed as potential therapies in heart failure [4].
Incretin mimetics are a new class of anti-diabetic drugs with
pleiotropic effects on insulin and glucagon secretion, gastric
emptying, satiety, and peripheral insulin sensitivity [5,6]. Gluca-
gon-like peptide-1 (GLP-1), administered by continuous subcuta-
neous infusion has been shown to increase myocardial glucose
delivery and improve left ventricular function in patients with
heart failure [7]. Studies to date however have not established
whether these changes are correlated with increased survival in
humans or animal models that have cardiomyopathy as the
primary defect. It also remains unclear whether this beneficial
effect is mediated through direct effects of incretin hormones on
contractile function or changes in myocardial glucose delivery [8].
In clinical studies, the presence of other long-standing environ-
mental risk factors (high fat diet, sedentary lifestyle, smoking) and
resulting co-morbidities (obesity, insulin, resistance, atherosclero-
sis, hypertension) together with the need for concomitant drug
therapy in human heart failure patients complicate efforts to
directly determine the effects of pharmacologic agents that alter
cardiac or systemic glucose homeostasis. We report here the
beneficial effects of the GLP-1 agonist exenatide, which can be
PLoS ONE | www.plosone.org 1 February 2011 | Volume 6 | Issue 2 | e17178administered by intermittent subcutaneous injection, on glucose
homeostasis, cardiac function and survival in a transgenic mouse
model of dilated cardiomyopathy.
Materials and Methods
Materials
The GLUT4 antagonist Ritonavir (Norvir) was obtained from
Abbott pharmaceuticals (Abbott Park, IL). The GLP-1 agonist
Exenatide (Byetta) was obtained from (Lilly, Indianapolis, IN).
GLUT4 antibody was custom produced by Invitrogen (Carlsbad,
CA). GLUT1 antibody was a gift from Dr Mike Mueckler
(Washington University, St Louis, MO). GAPDH monoclonal
antibody was purchased from Abcam (Cambridge MA). Anti
human/rat/mouse monoclonal pan-AKT antibody and rabbit
anti-phospho-AKT antibody were ordered from R& D Systems,
Inc (Minneapolis MN). AMPKa (F6) mouse antibody and
phospho-AMPKa (Thr 172) antibody were ordered from Cell
Signaling (Danvers, MA). Secondary anti-mouse and anti rabbit
antibodies were ordered from LI-COR (Lincoln, NE). Unless
noted, all other reagents were purchased from Sigma (St. Louis
MO).
Mouse Model
The TG9 dilated cardiomyopathy model was developed by
transgenic, high-level cardiac-specific expression of the cre
recombinase protein driven by the a-myosin heavy chain
promoter, as previously described [9]. The line is maintained in
the FVB/N strain background. The characteristic development
and progression of dilated cardiomyopathy in this mouse strain has
been extensively characterized [9,10,11].
Animal Procedures
All animal experiments were approved by the animal studies
committee at Washington University School of Medicine (Protocol
20080183). Mice were housed in the animal facility at Washington
University under standard light/dark cycles and fed standard
mouse chow diet and water ad libitum. For survival studies female
TG9 mice were given exenatide injections subcutaneously twice
daily (40 mg/kg/day) starting at 56 days of age with age-matched
littermate controls receiving an equal volume of normal saline.
Beginning at 75 days of age a subgroup of exenatide-treated
mice received ritonavir (10 mg/kg) by daily intraperitoneal
injection. Animals were closely monitored for activity, respiratory
rate, and general signs of distress for at least 90 minutes after each
injection.
Glucose tolerance
Following a 5 hour fast mice in the survival study group were
subjected to a 2 hour glucose tolerance test. At time zero 10%
dextrose (1 g/kg) was administered by an intraperitoneal injection
and blood was sampled from a tail vein at 15 minutes intervals.
Blood glucose was immediately determined using an Acenscia
Contour glucometer (Bayer Health care LLC, Tarrytown, NY).
Serum analyses
Serum insulin levels were determined by the DRTC immuno-
assay core facility at Washington University using a Singulex-
based assay (Alameda, CA). Serum triglyceride and cholesterol
levels were measured using commercially available kits (catalog
numbers 339-10 and 352-20, respectively) from Sigma (St. Louis,
MO). Serum NEFA levels were determined using reagents
obtained from Wako Chemicals (Richmond, Virginia).
Myocardial glucose uptake
Relative glucose uptake (Rg) was assessed by measuring 2-
deoxyglucose incorporation in left ventricular myocardium under
basal conditions following a 5-hour fast as previously described
[10,12,13].
Protein expression
Left ventricular myocardium was harvested from the mice
immediately following euthanasia and frozen in liquid nitrogen.
Lysates were prepared by homogenization in buffer containing 1%
triton X100 in PBS, Sigma protease inhibitor cocktail, sodium
vanadate 1 mM, sodium fluoride 50 mM, and sodium pyrophos-
phate 10 mM. Lysates were kept on ice for 15 minutes and cleared
by centrifugation at 15,000 g for 20 minutes at 4 degree Celsius.
Protein concentration was determined by the Bradford method (Bio-
rad, Hercules, CA). Western blot analysis was performed on 8 mgo f
total protein per lane using GLUT1 (1:1000) or GLUT4 (1:1000)
rabbit polyclonal antibody recognizing the C terminus of the
transporter, pan-AKT (1:5000), phospho-AKT (1:2000), AMPKa
(1:1000) and phospho-AMPKa (1:1000). GAPDH (1:5000) was used
as the control (used mouse monoclonal antibody). Protein band
intensities were quantified using Odyssey infrared imaging system
version 3.0 (LI-COR biosciences, Lincoln, NE, USA).
Brain natriuretic peptide RNA Quantification
RNA was purified and cDNA synthesized from 30 to 50 mg of
frozen left ventricular myocardium solubilized in trizol. Total RNA,
purified from the homogenate using the manufacturer’s instruction,
was treated with DNAse, followed by a phenol chloroform extraction.
cDNA was synthesized from 1.3 mg of total RNA using Super Script
First Strand Synthesis System (Invitrogen) according to the
manufacturer’s protocol. Quantitative Real Time PCR was then
performed using BNP sense (59 TCACCGCTGG GAGGTCACTC
39) and antisense (59GTGAGGCCTTGGTCCTTCAAG 39)p r i m e r
sequences. GAPDH was used as the reference gene and targeted
GAP-DH sense (59 CATCCACTGG TGCTGCCAAG 39)a n d
antisense (59GAGGGAGATGCTCAGTGTTGG 39)p r i m e r s .P C R
reactions were assembled as follows: Per 50 ul reaction 5 ul 10X KLA
pH 7.9 reaction buffer was used (DNA Polymerase Technology Inc.),
10 pM sense and antisense primers, 250 mM dNTPs, 1 mM MgCl2,
1.5 M betaine (Sigma B2629), 0.05 mL Cesium Klentaq AC (DNA
Polymerase Technology Inc.), 0.167X Cybr Green (Invitrogen
S7567), 23.7 uL molecular biology quality water (Sigma W4502).
1u Lo fc D N Aw a su s e dp e r5 0mL PCR reaction. Cycling conditions
consist of 1 time incubation at 60uCf o r5m i n ,9 4 uC for 30 sec, 60uC
30 sec, 68uC 1 min, 40 cycles. The qPCR was performed on a
Stratagene MX3005 qPCR thermal cycler.
Echocardiography
Transthoracic echocardiographic images were obtained on 70
day old TG9 mice after sedation with Avertin. The Acuson
Sequoia 256 echocardiography system with 15 MHz transducer
(Acuson corp., Mountain View, CA, USA) was used. Left
ventricular chamber dimensions and function were measured by
M-mode echocardiography. The internal diameter of the left
ventricle was measured in end-diastole and end-systole (LVIDd
and LVIDs). Systolic function was quantified by fractional
shortening, FS= (LVIDd -LVIDs)/LVIDd.
Results
Glucose homeostasis in TG9 mice
The TG9 mouse develops progressive dilated cardiomyop-
athy in a highly predictable manner. Cardiomyopathy in TG9
Exenatide and Heart Failure
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as marked by a steady increase in left ventricular diameter and
decrease in contractile function. Decompensated heart failure
and death occur between 11-13 weeks of life. In addition, TG9
mice exhibit many of the salient molecular and functional
changes observed in human heart failure including elevated
brain natriuretic peptide levels and a positive response to beta
blockers and ACE inhibitors [9]. Over this interval fasting
blood glucose levels rise in parallel with the worsening heart
failure. We previously reported that administration of the
GLUT4 antagonist ritonavir to 75 day old TG9 mice acutely
exacerbates glucose intolerance and precipitates decompensat-
ed heart failure [10]. This model therefore provides a useful
system to investigate the influence of improved glucose
homeostasis on myocardial function and survival.
To determine the effect of exenatide on glucose homeostasis,
female TG9 mice fed a standard chow diet first underwent
intraperitoneal glucose tolerance tests at 8 weeks of age. At this
age, TG9 mice appear overtly normal and have normal fasting
blood glucose levels but have echocardiographic evidence of mild
dilated cardiomyopathy [10]. Glucose tolerance tests (GTT) were
repeated after administering exenatide subcutaneously (40 mg/kg/
day divided into two daily doses) or vehicle for 14 days. Baseline
blood glucose levels and responses to GTT did not differ between
the two treatment groups (Figure 1). At 10 weeks of age, TG9 mice
receiving exenatide exhibited a response to glucose challenge that
was similar to untreated non-transgenic littermates with fasting
and peak blood glucose levels of 6.960.3 and 11.360.5 mmol/L,
respectively. In contrast, vehicle-treated TG9 mice developed a
significant worsening in both fasting blood glucose levels
(12.261.7 mmol/L) and glucose tolerance (peak glucose
21.860.7 mmol/L). None of the mice experienced detectable
hypoglycemia at any point during the study. As shown in Figure 2,
there was no difference in fasting serum insulin levels in 10 week
old exenatide-treated animals (0.2660.08 ng/ml) compared to
vehicle-treated littermate controls (0.2760.04 ng/ml). There was
also no difference in insulin levels 15 minutes (0.6960.06 ng/ml
exenatide vs 0.7460.15 ng/ml vehicle) or 30 minutes (0.2560.02
ng/ml exenatide vs 0.3060.06 ng/ml vehicle) after a 1 g/kg
intraperitoneal glucose load. Thus, exenatide appears to normalize
the response to glucose challenge in treated TG9 animals by
increasing insulin sensitivity rather than insulin secretion. Exena-
tide did not alter lipid profiles in TG9 mice (Table 1).
Glucose transporter expression and function
While the diabetic heart is known to use fatty acids almost
exclusively as a fuel [14,15], glucose utilization is increased in
hypertrophic cardiomyopathy despite the development of insulin
resistance [16]. This is accompanied by increased expression of the
constitutively active glucose transporter GLUT1 [17]. In TG9
mice GLUT1 levels are similarly increased whereas the expression
of GLUT4, the predominant glucose transporter in the adult
heart, is unchanged [10]. We therefore examined whether GLUT
expression was altered by exenatide in TG9 mice. At 75 days of
age, total myocardial GLUT4 protein levels were increased by
40% in exenatide-treated versus non-treated TG9 mice whereas
GLUT1 protein levels were unchanged (Figure 3A, B). Although
previous studies have shown that exenatide can increase the
expression of GLUT1, which is constitutively present on plasma
membranes of multiple tissues including the heart and skeletal
muscle [18], we did not detect any differences in total GLUT1
levels possibly because heart failure alone induces maximal up-
regulation of this transporter [10].
Measurement of total AKT revealed no difference between the
2 groups at 70 days (Figure 3C). Phosphorylated AKT, however,
was approximately 40% higher in the exenatide-treated animals.
Similarly, while AMPKa levels were unchanged, phosphorylated
AMPKa was increased by 67% in the exenatide versus vehicle-
treated mice (Figure 3D).
We next determined whether exenatide affects relative cardiac
glucose uptake in TG9 mice. We have previously demonstrated
that in 75 day old TG9 mice 2-deoxyglucose (2-DG) uptake is
reduced to approximately one third of that observed in non-
transgenic littermate control animals, consistent with the develop-
ment of insulin resistance in these animals [10]. Acute treatment of
56 day old TG-9 mice with exenatide did not alter basal 2-
deoxyglucose uptake into left ventricular myocardium
(1063.8 mmol/100 g/min) compared to vehicle-treated animals
(14.568.3 mmol/100 g/min). However, as shown in Figure 4A,
after 3 weeks of exenatide treatment, 2-DG uptake was
significantly increased (37.765.9 mmol/100 g/min) compared to
vehicle treated animals (19.863.6 mmol/100 g/min, p,0.05).
Under these fasting conditions, basal skeletal muscle 2-DG uptake
was low and no significant change was detected (data not shown).
We have previously shown that acute administration of the
GLUT4 antagonist ritonavir produces a significant reduction in
myocardial glucose uptake in TG9 mice [10]. Given that chronic
Figure 1. Intraperitoneal glucose tolerance tests (1 g/kg) on age-matched female TG9 mice following a 5 hour fast. A. Baseline
responses at 8 weeks of age. B. Following 2 weeks of treatment with either vehicle or exenatide (Age 10 weeks). Data is shown as the mean 6 SEM
(n=4-6). *p,0.01, ANOVA.
doi:10.1371/journal.pone.0017178.g001
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glucose uptake, we reasoned that this GLP-1 agonist should
ameliorate the detrimental effect of ritonavir. TG9 mice were
chronically treated with exenatide or vehicle starting at 56 days of
life and then exposed to a single dose of intraperitoneal ritonavir
(10 mg/kg) 15 minutes prior to tail vein injection of 2-
deoxyglucose (2-DG). As shown in Figure 4B, myocardial glucose
uptake was significantly increased (58.361.0 mmol/100 g/min) in
ritonavir-treated mice with chronic prior exenatide exposure
compared to animals that had received vehicle over this same
interval (15.467.9 mmol/100 g/min, p=0.002).
Cardiac function
The effect of exenatide on cardiac contractile function was
assessed by echocardiography in 70 day-old TG9 mice. It was
noted that the vehicle-treated mice were hypothermic and
bradycardic compared to exenatide-treated animals (Table 1).
Bradycardia is commonly observed in rodents with severe heart
failure and is thought to be a compensatory mechanism to increase
left ventricular filling time in mice with normally fast heart rates
[19]. Upon warming the control animals to normothermia, heart
rates remained lower but this difference did not reach statistical
significance. Systolic function, as assessed by fractional shortening
was significantly improved in the exenatide-treated mice. Left
ventricular remodeling, as assessed by the left ventricular diameter
and posterior wall thickness in end-diastole, was similar in the
treated and untreated animals (Table 2).
For an independent marker of the severity of heart failure, we
measured mRNA expression of brain natriuretic peptide (BNP) in
the left ventricle of exenatide-treated mice and the control
counterparts. As shown in Figure 5, BNP levels were significantly
lower in the exenatide-treated animals compared to littermate
vehicle-treated control TG9 mice (0.2860.07 versus 1.060.26
arbitrary units, respectively, p=0.02).
Survival analysis
Although various genetic and pharmacologic interventions can
improve markers of cardiac function in heart failure, prolongation
of survival is the gold standard outcome. The highly reproducible
progression of heart failure and death in the TG9 mice provides a
means to assess survival as an endpoint. Untreated TG9 mice
typically die between 11–13 weeks of age (mean 8162 days for
females). In addition to improving glucose tolerance and cardiac
function, exenatide significantly improved survival of TG9 mice
compared to vehicle-treated littermate controls (Figure 6A)
(89.662 days vs. 83.060.6 days). This effect is comparable to
the improvement afforded by the ACE inhibitor captopril [9].
Consistent with our previous study [10], intraperitoneal
injection of ritonavir starting at 75 days of age produced
immediate signs of decompensated heart failure including
decreased activity and tachypnea (data not shown). The
decompensation was transient, consistent with the pharmacoki-
netics of drug elimination [20], but sometimes caused death. As
shown in Figure 6B, when ritonavir administration was continued
daily, survival was significantly reduced (78.660.6 days, p,0.05).
Mice treated with both ritonavir and exenatide survived a mean of
84.661.0 days, which is significantly longer than mice given
ritonavir alone and is close to the survival age of TG9 mice given
vehicle alone. This further supports a significant influence of
glucose transport on overall survival in this rodent model.
Discussion
Maladaptive neurohormonal signaling involving the renin-
angiotensin-aldosterone and adrenergic systems are fundamental
pathophysiological processes in heart failure. Insulin resistance and
abnormal myocardial glucose uptake also exist, but whether they are
adaptive or not is less clear. The present analyses of pharmacologic
manipulations in an animal model of dilated cardiomyopathy
indicate that the metabolic changes are maladaptive. Exenatide, an
incretin mimetic, improves glucose homeostasis, delays the progres-
sion of heart failure and most importantly prolongs survival. This
study extends previous reports showing that GLP-1 has beneficial
short-termeffectsoncardiaccontractilityandcardiacoutputinheart
failure patients [7] and provides further support for a causal link
between changes in glucose uptake and cardiac function. Our data
are also consistent with the increased survival observed by Poornima
and colleagues in heart failure prone rats given a 3-month
continuous infusion of GLP-1 [21]. In their chronically hypertensive
rat model, heart failure occurs secondarily to the metabolic
syndrome phenotype. In contrast, in the TG9 mouse heart failure
is a primary effect of a cardiac-specific transgene. Therefore, we
demonstrate that treatment of insulin resistance arising secondarily
from a primary cardiomyopathy is beneficial.
Complex factors involving the heart, other organs or systems
and their interactions clearly influence survival in heart failure.
The beneficial effects of exanatide on cardiac function and survival
may therefore be mediated through drug-induced changes in the
heart, the body, or both. Exenatide and ritonavir can have
different influences on individual factors; their combined effects
determine the pathophysiologic variables related to glucose
Figure 2. Insulin levels were obtained on age matched female
TG9 mice at 10 weeks following a 5 hour fast at 0, 15 and 30
minutes after an intraperitoneal glucose dose (1 g/kg). Data
shown as the mean 6 SEM (n=4 per group). *, p,0.05 compared to 0
minute insulin level.
doi:10.1371/journal.pone.0017178.g002
Table 1. Lipid profile of TG9 mice.
Parameter Exenatide (n=4) Vehicle (n=4) p-value
Triglycerides (mg/dl) 135.0622.5 140.9629.78 0.88
Cholesterol (mg/dl)
Free
106.568.47 103.466.88 0.79
Free Fatty Acids (mM) 0.9760.31 0.6160.13 0.32
Lipid profiles were measured in plasma of mice at 70 days of life. Data is shown
as average +/2 SEM. P-values determined by unpaired student’s t-test.
doi:10.1371/journal.pone.0017178.t001
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tide can normalize whole-body insulin sensitivity and myocardial
glucose uptake in mice that have advanced dilated cardiomyop-
athy, cardiac contractile function and survival are improved but
not to perfect health. Exenatide in the failing heart can also
abrogate the inhibitory effect of ritonavir on myocardial glucose
uptake. However, while protecting against death from acute
cardiac decompensation precipitated by ritonavir, exenatide does
not completely prevent it, as shown by the small but significant
difference in survival between animals given exenatide and
ritonavir or exenatide alone. Ritonavir may therefore have
extracardiac effects not completely rescued by exenatide treat-
ment, e.g., impaired respiratory mechanics in the setting of acute
pulmonary congestion, or less likely unknown cardiac effects
unrelated to myocardial glucose transport.
Although exenatide clearly has complex effects in heart failure,
the expression of the G-protein-coupled receptor GLP-1R in
cardiomyocytes supports the role of a direct effect on the heart.
Studies in GLP-1R
2/2 mice indicate that signaling through this
receptor affects both heart rate and contractile function [22].
Furthermore, native GLP-1 has been shown to improve cardiac
reconditioning in isolated perfused rat hearts [23]. Signaling
through GLP-1 could facilitate activation of AKT or AMPK
signaling and consequent GLUT4 translocation.
Since insulin-stimulated activation of AKT leads to GLUT4
translocation, the increased levels of phosphorylated AKT
Figure 3. Western blot analysis and protein quantification of left ventricular myocardium harvested from 70-day-old TG9 mice. A.
GLUT4 B. GLUT1 C. pan-AKT and phospho-AKT. D. AMPKa and phospho-AMPK. For each protein, the top panel represents expression as determined
using antibody recognizing the protein of interest. Bottom panel: Data is represented as the mean protein intensity normalized to GAPDH from 4–6
independent mice. Each western blot was performed in triplicate. Values are expressed as the mean 6 SEM; * indicates p,0.03, student’s t-test.
doi:10.1371/journal.pone.0017178.g003
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myocardial glucose uptake. The augmented glucose uptake
observed in our study can also be mediated through AMPKa
activation. AMPK is a key molecular player in energy homeostasis
at both cellular and whole-body levels [25]. In the heart, AMPK
activation is known to increase cardiac glucose utilization by a
number of different mechanisms including the translocation of
GLUT4 to the sarcolemma, with a resulting augmentation of
glucose uptake [26]. Metformin, which activates AMPK similarly
prevents the progression of heart failure in dogs [27]. It remains to
be determined whether this AMPK activation is mediated directly
through the myocardial GLP-1 receptor or indirectly through
improved contractile function. Investigation of the effects of
exenatide in GLP-1R
2/2 and GLUT4
2/2 mice will provide
further insight into direct versus indirect drug effects. Exenatide
could also have effects in chronic heart failure that are unrelated to
glucose-transport such as the inhibition of apoptosis [24].
Ideally, any novel heart failure therapy, whether it inhibits a
maladaptive or supplements an adaptive response, should be free
of serious side-effects. GLP-1 agonists, which are relatively new
agents in the treatment of type 2 diabetes, possess several benefits
over other therapies including less risk for hypoglycemia,
modulation of satiety with less weight gain, and preservation of
beta cell mass [6]. The pharmacokinetic profile of exenatide allows
intermittent subcutaneous dosing rather than continuous infusion
as is required of GLP-1. However, exenatide may be linked to the
development of pancreatitis [6], and the potential for interactions
with other drugs commonly prescribed in heart failure patients
exists. Thus continued research into and development of incretin-
based therapies that mimic GLP-1 or prevent its degradation are
worthwhile.
Whether incretin-based drugs like exenatide or dipeptidyl
peptidase inhibitors that augment endogenous GLP-1 levels can
provide an additional benefit when used in combination with
standard heart failure therapies is an open question. The current
findings may also have physiologic relevance to other situations
such as the ischemic heart, which loses its normal substrate
flexibility and becomes more dependent upon glucose as a
Figure 4. Left ventricular myocardial glucose uptake in 75-day
old female TG9 mice. A. TG9 mice treated with vehicle or exenatide
starting at 56 days of age as determined by [
3H]-2-deoxyglucose
incorporation following a 5-h fast (n=9 and 8 per group). B. TG9 mice
treated with vehicle or exenatide as in panel A were treated with
ritonavir (10 mg/kg) administered by i.p. injection 15 minutes prior to
measurement of [
3H]-2-deoxyglucose incorporation (n=6 and 3
respectively per group). Tissue glucose metabolic index (Rg’); *p,0.05.
doi:10.1371/journal.pone.0017178.g004
Table 2. Echocardiography of TG9 mice.
Parameter Exenatide (n=6) Vehicle (n=8) p-value
Body weight (g)
Age 50 days 21.760.38 20.260.42 0.51
Age 70 days 21.960.31 20.960.5 0.23
Heart rate (beats per
minute)
491619 466614 0.34
Basal body Temperature
(uC)
36.460.1 34.760.2 0.014
LVPWd 0.7060.05 0.7360.02 0.66
LVIDs 2.8160.12 3.1760.12 0.048
LVIDd 4.0060.13 3.9860.12 0.98
Fractional shortening (%) 26.861.4 20.761.8 0.03
Transthoracic echocardiography performed on 70 day old TG9 mice. Exenatide
(or vehicle) was administered subcutaneously at a dose of 40 mg/kg/day
(divided b.i.d.) starting at 56 days of age. Hypothermic animals were warmed to
36uC immediately prior to obtaining echocardiograms. LVPWd, left ventricular
posterior wall diastolic dimension. LVIDs, left ventricular internal diameter in
systole. LVIDd, left ventricular internal diameter in diastole. Data is shown as the
average +/2 SEM.
doi:10.1371/journal.pone.0017178.t002
Figure 5. RT- PCR for brain naturetic peptide measurement in
the TG9 left ventricular tissue harvested at 70 days of life. Mice
were treated with exenatide or vehicle (40 mg/kg/day divided b.i.d.)
starting at 56 days. n=4 per group, p-value =0.02.
doi:10.1371/journal.pone.0017178.g005
Exenatide and Heart Failure
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survival benefit of exenatide in a murine model will translate to
human patients. We suggest that the strong conservation of
molecular pathways in mouse and human cardiovascular physi-
ology provides a compelling rationale to address this question.
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